How much did Realcan Pharmaceutical Group Co achieve in EBIT for the current year?
In the current year, Realcan Pharmaceutical Group Co has achieved an EBIT of -11.9 M CNY.
Realcan Pharmaceutical Group Co EBIT 2024
Realcan Pharmaceutical Group Co EBIT
-11.9 M CNY
Ticker
002589.SZ
ISIN
CNE1000013X5
In 2024, Realcan Pharmaceutical Group Co's EBIT was -11.9 M CNY, a -97.12% increase from the -412.75 M CNY EBIT recorded in the previous year.
The Realcan Pharmaceutical Group Co EBIT history
| YEAR | EBIT (undefined CNY) |
|---|---|
| 2023 | -0.01 |
| 2022 | -0.41 |
| 2021 | 0.76 |
| 2020 | 1.33 |
| 2019 | 2.38 |
| 2018 | 2.58 |
| 2017 | 1.99 |
| 2016 | 0.95 |
| 2015 | 0.38 |
| 2014 | 0.31 |
| 2013 | 0.26 |
| 2012 | 0.19 |
| 2011 | 0.11 |
| 2010 | 0.1 |
| 2009 | 0.07 |
| 2008 | 0.05 |
Realcan Pharmaceutical Group Co Revenue, EBIT, Net Income CNE1000013X5 ·
3 years
5 years
10 years
Max
Revenue
EBIT
Net Income
Details
Revenue, EBIT and Profit
ⓘUnderstanding Revenue, EBIT, and Income
Gain insights into Realcan Pharmaceutical Group Co, a comprehensive overview of its financial performance can be obtained by analyzing the Revenue, EBIT, and Income chart. Revenue represents the total income generated by Realcan Pharmaceutical Group Co from its primary operations, showcasing the company’s ability to attract and retain clients. EBIT, or Earnings Before Interest and Taxes, indicates the company’s operational profitability, free from the influence of tax and interest expenses. The Income section reflects Realcan Pharmaceutical Group Co’s net earnings, an ultimate measure of its financial health and profitability.
Yearly Analysis and Comparisons
Observe the yearly bars to understand the annual performance and growth of Realcan Pharmaceutical Group Co. Compare the Revenue, EBIT, and Income to evaluate the company’s efficiency and profitability. A higher EBIT compared to the previous year suggests an improvement in operational efficiency. Likewise, an increase in Income indicates enhanced overall profitability. Analyzing the year-to-year comparison assists investors in understanding the company’s growth trajectory and operational efficiency.
Utilizing Expectations for Investment
The expected values for the forthcoming years offer investors a glimpse into Realcan Pharmaceutical Group Co’s anticipated financial performance. Analyzing these projections alongside historical data aids in making informed investment decisions. Investors can gauge the potential risks and returns, aligning their investment strategies accordingly to optimize profitability and mitigate risks.
Investment Insights
Leveraging the comparison between Revenue and EBIT helps in assessing Realcan Pharmaceutical Group Co’s operational efficiency, while the Revenue and Income comparison reveals the net profitability after accounting for all expenses. Investors can derive valuable insights by meticulously analyzing these financial parameters, laying the foundation for strategic investment decisions aimed at capitalizing on Realcan Pharmaceutical Group Co’s growth potential.
Realcan Pharmaceutical Group Co Revenue, EBIT and net profit per share
| Date | Realcan Pharmaceutical Group Co Revenue | Realcan Pharmaceutical Group Co EBIT | Realcan Pharmaceutical Group Co Net Income |
|---|---|---|---|
| 2023 | 8.03 B undefined | -11.9 M undefined | 20.32 M undefined |
| 2022 | 12.31 B undefined | -412.75 M undefined | -1.83 B undefined |
| 2021 | 21.06 B undefined | 756.78 M undefined | 131.18 M undefined |
| 2020 | 27.2 B undefined | 1.33 B undefined | 261 M undefined |
| 2019 | 35.26 B undefined | 2.38 B undefined | -928 M undefined |
| 2018 | 33.92 B undefined | 2.58 B undefined | 771 M undefined |
| 2017 | 23.29 B undefined | 1.99 B undefined | 1.01 B undefined |
| 2016 | 15.62 B undefined | 951 M undefined | 591 M undefined |
| 2015 | 9.75 B undefined | 381 M undefined | 236 M undefined |
| 2014 | 7.79 B undefined | 309 M undefined | 181 M undefined |
| 2013 | 5.93 B undefined | 260 M undefined | 144 M undefined |
| 2012 | 4.62 B undefined | 186 M undefined | 111 M undefined |
| 2011 | 3.2 B undefined | 108 M undefined | 59 M undefined |
| 2010 | 2.21 B undefined | 98 M undefined | 62 M undefined |
| 2009 | 1.6 B undefined | 73 M undefined | 45 M undefined |
| 2008 | 1.15 B undefined | 47 M undefined | 29 M undefined |
| Revenue | EBIT | Net Income | |
|---|---|---|---|
| 2008 | 1.15 B CNY | 47 M CNY | 29 M CNY |
| 2009 | 1.6 B CNY | 73 M CNY | 45 M CNY |
| 2010 | 2.21 B CNY | 98 M CNY | 62 M CNY |
| 2011 | 3.2 B CNY | 108 M CNY | 59 M CNY |
| 2012 | 4.62 B CNY | 186 M CNY | 111 M CNY |
| 2013 | 5.93 B CNY | 260 M CNY | 144 M CNY |
| 2014 | 7.79 B CNY | 309 M CNY | 181 M CNY |
| 2015 | 9.75 B CNY | 381 M CNY | 236 M CNY |
| 2016 | 15.62 B CNY | 951 M CNY | 591 M CNY |
| 2017 | 23.29 B CNY | 1.99 B CNY | 1.01 B CNY |
| 2018 | 33.92 B CNY | 2.58 B CNY | 771 M CNY |
| 2019 | 35.26 B CNY | 2.38 B CNY | -928 M CNY |
| 2020 | 27.2 B CNY | 1.33 B CNY | 261 M CNY |
| 2021 | 21.06 B CNY | 756.78 M CNY | 131.18 M CNY |
| 2022 | 12.31 B CNY | -412.75 M CNY | -1.83 B CNY |
| 2023 | 8.03 B CNY | -11.9 M CNY | 20.32 M CNY |
Realcan Pharmaceutical Group Co stock margins CNE1000013X5 ·
The Realcan Pharmaceutical Group Co margin analysis displays the gross margin, EBIT margin, as well as the profit margin of Realcan Pharmaceutical Group Co. The EBIT margin (EBIT/sales) indicates the percentage of sales that remains as operating profit. The profit margin shows the percentage of sales that remains for Realcan Pharmaceutical Group Co.
3 years
5 years
10 years
Max
Gross margin
EBIT margin
Profit margin
Details
Margin
ⓘUnderstanding Gross Margin
The gross margin, expressed as a percentage, delineates the gross profit made from the Realcan Pharmaceutical Group Co's sales revenue. A higher gross margin percentage indicates that the Realcan Pharmaceutical Group Co retains more revenue after accounting for the costs of goods sold. Investors use this metric to gauge financial health and operational efficiency, as well as to compare it with competitors and industry averages.
EBIT Margin Analysis
EBIT margin represents the Realcan Pharmaceutical Group Co's earnings before interest and taxes. Analyzing the EBIT margin over different years provides insights into the operational profitability and efficiency, excluding the effects of financial leverage and tax structure. A growing EBIT margin over the years signifies improving operational performance.
Revenue Margin Insights
The revenue margin demonstrates the Realcan Pharmaceutical Group Co's total revenue generated. When comparing the revenue margin year over year, investors can gauge the Realcan Pharmaceutical Group Co's growth and market expansion. It is essential to compare the revenue margin with the gross and EBIT margins to understand the cost and profit structures better.
Interpreting Expectations
The expected values for gross, EBIT, and revenue margins provide future financial outlook of the Realcan Pharmaceutical Group Co. Investors should compare these expectations with historical data to understand potential growth and risk factors. It is crucial to consider the underlying assumptions and methodologies used in projecting these expected values to make informed investment decisions.
Comparative Analysis
Comparing the gross, EBIT, and revenue margins, both yearly and over multiple years, enables investors to perform a comprehensive analysis of the Realcan Pharmaceutical Group Co's financial health and growth prospects. Evaluating the trends and patterns in these margins helps in identifying strengths, weaknesses, and potential investment opportunities.
Realcan Pharmaceutical Group Co Margin History
| Realcan Pharmaceutical Group Co Gross margin | Realcan Pharmaceutical Group Co Profit margin | Realcan Pharmaceutical Group Co EBIT margin | Realcan Pharmaceutical Group Co Profit margin |
|---|---|---|---|
| 2023 | 10.28 % | -0.15 % | 0.25 % |
| 2022 | 13.58 % | -3.35 % | -14.88 % |
| 2021 | 18.23 % | 3.59 % | 0.62 % |
| 2020 | 18.29 % | 4.87 % | 0.96 % |
| 2019 | 19.34 % | 6.75 % | -2.63 % |
| 2018 | 19.15 % | 7.6 % | 2.27 % |
| 2017 | 18.44 % | 8.53 % | 4.33 % |
| 2016 | 15.67 % | 6.09 % | 3.78 % |
| 2015 | 10.97 % | 3.91 % | 2.42 % |
| 2014 | 9.05 % | 3.97 % | 2.32 % |
| 2013 | 8.59 % | 4.39 % | 2.43 % |
| 2012 | 8.16 % | 4.02 % | 2.4 % |
| 2011 | 8.04 % | 3.38 % | 1.85 % |
| 2010 | 8.13 % | 4.43 % | 2.8 % |
| 2009 | 8.43 % | 4.56 % | 2.81 % |
| 2008 | 8.72 % | 4.1 % | 2.53 % |
| Gross margin | EBIT margin | Profit margin | |
|---|---|---|---|
| 2008 | 8.72 % | 4.1 % | 2.53 % |
| 2009 | 8.43 % | 4.56 % | 2.81 % |
| 2010 | 8.13 % | 4.43 % | 2.8 % |
| 2011 | 8.04 % | 3.38 % | 1.85 % |
| 2012 | 8.16 % | 4.02 % | 2.4 % |
| 2013 | 8.59 % | 4.39 % | 2.43 % |
| 2014 | 9.05 % | 3.97 % | 2.32 % |
| 2015 | 10.97 % | 3.91 % | 2.42 % |
| 2016 | 15.67 % | 6.09 % | 3.78 % |
| 2017 | 18.44 % | 8.53 % | 4.33 % |
| 2018 | 19.15 % | 7.6 % | 2.27 % |
| 2019 | 19.34 % | 6.75 % | -2.63 % |
| 2020 | 18.29 % | 4.87 % | 0.96 % |
| 2021 | 18.23 % | 3.59 % | 0.62 % |
| 2022 | 13.58 % | -3.35 % | -14.88 % |
| 2023 | 10.28 % | -0.15 % | 0.25 % |
Realcan Pharmaceutical Group Co Aktienanalyse
What does Realcan Pharmaceutical Group Co do?
Realcan Pharmaceutical Group Co. Ltd is a Chinese pharmaceutical company based in the city of Chengdu. The company was founded in 2009 and has since built a deep knowledge and understanding of the pharmaceutical industry in the Chinese market. Since its inception, the company has developed a wide range of drugs and health products. Realcan Pharmaceutical Group Co. Ltd has established itself as one of the largest and most reliable pharmaceutical companies in China, specializing in the development, manufacturing, and marketing of pharmaceuticals. The business model of Realcan Pharmaceutical Group Co. Ltd is based on a variety of growth drivers, including entering new markets and developing new products. The company has always focused on leveraging the experience and expertise of its employees to deliver innovations and high-quality products that have a positive impact on consumer health. The company places the highest value on the quality, safety, and effectiveness of its products and services. Realcan Pharmaceutical Group Co. Ltd offers a wide range of products, ranging from drugs and medications to health products and supplements. The company specializes in various areas, including oncology, dermatology, cardiology, neurology, respiratory diseases, gastroenterology, and endocrinology. Several products from Realcan have already received approval from the Chinese health authority and are available on the market. Some of the company's most well-known products include the anti-tumor drugs Nifuratel and Nifuratrone, the cardiology product Cardio Protect, and the neurology product Neuro Relief. Realcan Pharmaceutical Group Co. Ltd also specializes in the production of traditional Chinese medicine and herbal medicine. Traditional Chinese medicine is gaining increasing importance in the Chinese market as it is considered an effective alternative to Western medicine. Realcan Pharmaceutical Group Co. Ltd is committed to promoting research and development in the field of traditional Chinese medicine. The company works closely with universities and other research institutions to develop effective and safe herbal medicine. Realcan Pharmaceutical Group Co. Ltd also specializes in entering international markets. The company exports its products to various countries, including the United States, Australia, France, India, and Japan. The company places great emphasis on complying with international standards and ensuring the safety and quality of its products. In summary, Realcan Pharmaceutical Group Co. Ltd is an innovative Chinese pharmaceutical company that offers a wide range of pharmaceutical products and services. The company has established itself as a reliable brand in the field of drug development and manufacturing and is committed to adhering to global standards to strengthen customer trust. Realcan Pharmaceutical Group Co. Ltd will continue to play an important role in the Chinese and international markets and consolidate its leadership position as a reliable and innovative pharmaceutical company. Realcan Pharmaceutical Group Co ist eines der beliebtesten Unternehmen auf Eulerpool.com.EBIT Details
Analyzing Realcan Pharmaceutical Group Co's EBIT
Realcan Pharmaceutical Group Co's Earnings Before Interest and Taxes (EBIT) represents the company's operating profit. It is calculated by deducting all operating expenses, including the cost of goods sold (COGS) and operating expenses, from the total revenue, but before accounting for interest and taxes. It provides insights into the company’s operational profitability, excluding the impacts of financing and tax structures.
Year-to-Year Comparison
A yearly comparison of Realcan Pharmaceutical Group Co's EBIT can reveal trends in the company’s operational efficiency and profitability. An increase in EBIT over the years can indicate enhanced operational efficiency or growth in revenue, while a decrease might raise concerns about increased operating costs or declining sales.
Impact on Investments
Realcan Pharmaceutical Group Co's EBIT is a significant metric for investors. A positive EBIT suggests that the company is generating enough revenue to cover its operating expenses, an essential aspect for assessing the company’s financial health and stability. Investors closely monitor EBIT to gauge the company’s profitability and potential for future growth.
Interpreting EBIT Fluctuations
Fluctuations in Realcan Pharmaceutical Group Co’s EBIT can be due to variations in revenue, operating expenses, or both. An increasing EBIT indicates improved operational performance or increased sales, while a declining EBIT can signal rising operational costs or reduced revenue, prompting a need for strategic adjustments.
Frequently Asked Questions about Realcan Pharmaceutical Group Co Stock
What is EBIT?
EBIT stands for Earnings Before Interest and Taxes and refers to the profit before interest and taxes of a company Realcan Pharmaceutical Group Co.
How has the EBIT of Realcan Pharmaceutical Group Co developed in recent years?
The EBIT of Realcan Pharmaceutical Group Co has increased by -97.116% decreased compared to the previous year.
What does EBIT mean for investors?
EBIT provides investors with insights into a company's profitability as it reflects the profit before interest expenses and taxes.
Why is EBIT an important indicator for investors?
Since EBIT provides a more direct insight into a company's profit than net income, it is an important indicator for investors to assess the profitability of a company.
Why do EBIT values fluctuate?
EBIT values can fluctuate as they are influenced by various factors, such as revenue, costs, and tax effects.
What role does tax burden play in EBIT?
Tax burdens have a direct impact on a company's EBIT, as they are deducted from the profit.
How is EBIT presented in the balance sheet of the company Realcan Pharmaceutical Group Co?
The EBIT of Realcan Pharmaceutical Group Co is listed in the income statement.
Can EBIT be used as a single indicator for evaluating a company?
EBIT is an important indicator for evaluating a company, but additional financial ratios should also be considered to get a comprehensive picture.
Why is EBIT not equal to net profit?
The net profit of a company includes taxes and interest, while EBIT represents the profit before interest and taxes.
How much dividend does Realcan Pharmaceutical Group Co pay?
Over the past 12 months, Realcan Pharmaceutical Group Co paid a dividend of 0.01 CNY . This corresponds to a dividend yield of about 0.41 %. For the coming 12 months, Realcan Pharmaceutical Group Co is expected to pay a dividend of 0.01 CNY.
What is the dividend yield of Realcan Pharmaceutical Group Co?
The current dividend yield of Realcan Pharmaceutical Group Co is 0.41 %.
When does Realcan Pharmaceutical Group Co pay dividends?
Realcan Pharmaceutical Group Co pays a quarterly dividend. This is distributed in the months of July, July, August, July.
How secure is the dividend of Realcan Pharmaceutical Group Co?
Realcan Pharmaceutical Group Co paid dividends every year for the past 0 years.
What is the dividend of Realcan Pharmaceutical Group Co?
For the upcoming 12 months, dividends amounting to 0.01 CNY are expected. This corresponds to a dividend yield of 0.41 %.
In which sector is Realcan Pharmaceutical Group Co located?
Realcan Pharmaceutical Group Co is assigned to the 'Health' sector.
Wann musste ich die Aktien von Realcan Pharmaceutical Group Co kaufen, um die vorherige Dividende zu erhalten?
To receive the latest dividend of Realcan Pharmaceutical Group Co from 6/4/2024 amounting to 0.013 CNY, you needed to have the stock in your portfolio before the ex-date on 6/4/2024.
When did Realcan Pharmaceutical Group Co pay the last dividend?
The last dividend was paid out on 6/4/2024.
What was the dividend of Realcan Pharmaceutical Group Co in the year 2023?
In the year 2023, Realcan Pharmaceutical Group Co distributed 0.018 CNY as dividends.
In which currency does Realcan Pharmaceutical Group Co pay out the dividend?
The dividends of Realcan Pharmaceutical Group Co are distributed in CNY.
Stock savings plans offer an attractive way for investors to build wealth over the long term. One of the main advantages is the so-called cost-average effect: by regularly investing a fixed amount in stocks or stock funds, you automatically buy more shares when prices are low, and fewer when they are high. This can lead to a more favorable average price per share over time. In addition, stock savings plans allow small investors access to expensive stocks, as they can participate with small amounts. Regular investment also promotes a disciplined investment strategy and helps to avoid emotional decisions, such as impulsive buying or selling. Furthermore, investors benefit from the potential appreciation of the stocks as well as from dividend distributions, which can be reinvested, enhancing the compounding effect and thus the growth of the invested capital.
Andere Kennzahlen von Realcan Pharmaceutical Group Co
Our stock analysis for Realcan Pharmaceutical Group Co Revenue stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of Realcan Pharmaceutical Group Co Revenue. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.
- Realcan Pharmaceutical Group Co Revenue
- Realcan Pharmaceutical Group Co Net Income
- Realcan Pharmaceutical Group Co P/E
- Realcan Pharmaceutical Group Co P/S
- Realcan Pharmaceutical Group Co EBIT
- Realcan Pharmaceutical Group Co Dividend
- Realcan Pharmaceutical Group Co Stocks
- Realcan Pharmaceutical Group Co Market capitalization
- Realcan Pharmaceutical Group Co Debt
- Realcan Pharmaceutical Group Co Liabilities
- Realcan Pharmaceutical Group Co Equity
- Realcan Pharmaceutical Group Co AAQS
- Realcan Pharmaceutical Group Co Employees
- Realcan Pharmaceutical Group Co ROE
- Realcan Pharmaceutical Group Co ROA
- Realcan Pharmaceutical Group Co ROCE